-
Palonosetron and Chemotherapy-Induced Nausea and Vomiting
2026-08-19
Ruhlmann and Herrstedt’s review examines why palonosetron differs pharmacologically from earlier 5-HT3 receptor antagonists and whether those differences translate into better prevention of chemotherapy-induced nausea and vomiting. Its practical contribution is a balanced interpretation of comparative trials, emphasizing improved control of delayed symptoms while showing that regimen design, corticosteroids, and NK1 antagonists remain essential to comprehensive prophylaxis.
-
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-18
A 2025 study found that naturally occurring angiotensin peptides can enhance SARS-CoV-2 spike-protein binding to AXL and, for angiotensin IV, to ACE2 and NRP1. Its sequence-comparison strategy highlights N-terminal truncation and tyrosine modification as important determinants, while also defining an assay-based framework for studying links between renin–angiotensin biology and viral entry.
-
Beclin1, Ferroptosis, and Doxorubicin Liver Injury
2026-08-18
A 2026 study identifies Beclin1 as a contributor to doxorubicin-induced liver injury by linking excessive autophagy with ferroptotic lipid damage. Beclin1 knockdown and DHODH overexpression reduced oxidative stress, ferroptosis, and liver injury, providing a mechanistic framework for layered lipid peroxidation measurement.
-
Machine Learning for Cross-Cell-Line MoA Prediction
2026-08-17
Warchal, Dawson, and Carragher evaluated whether machine learning models trained on high-content cellular phenotypes can predict compound mechanism of action across genetically and morphologically distinct breast cancer cell lines. Their results show that convolutional neural networks perform comparably to ensemble tree classifiers within individual cell lines, but engineered-feature models transfer more effectively to an unseen cell line.
-
Trichostatin A and the Ferroptosis Frontier
2026-08-17
Trichostatin A (TSA) is more than a benchmark HDAC inhibitor: it is a controllable entry point for connecting chromatin acetylation, tumor-cell state, mitochondrial metabolism, and ferroptosis. This article translates established TSA biology and findings on mitochondrial calcium–GPX4 signaling into a rigorous strategy for cancer and epigenetic research.
-
IDO1 Inhibition and Tumor-Intrinsic STAT3 Activation
2026-08-16
The reference study reveals that pharmacological inhibition of apo-IDO1 can activate antitumor immune cells while simultaneously inducing an IL-6–JAK2/STAT3 survival program in tumor cells. Its single-cell analysis supports combination strategies that pair IDO1 inhibition with pathway blockade, while also clarifying why immune activation alone may not translate into tumor control.
-
ROS-Responsive Nanoparticles Drive Cuproptosis
2026-08-15
The reference study develops ROS-sensitive nanoparticles that co-deliver elesclomol and copper to induce cuproptosis in bladder cancer models. Its combination with αPD-L1 links copper-dependent tumor cell death to immune microenvironment remodeling, providing a mechanistic rationale for combined nanomedicine and checkpoint blockade.
-
Butyrate Drives Ferroptosis in Lung Cancer Stem Cells
2026-08-14
The 2024 Heliyon study identifies a dual mechanism by which butyrate weakens lung cancer stemness: lysosomal Fe2+ recruitment and destabilization of the antioxidant transporter SLC7A11. Its experiments connect these events to ferroptosis, reduced stem-like behavior, tumorigenesis, and altered chemotherapy sensitivity, providing a mechanistic framework for cancer biology research.
-
Reactive Oxygen Species Assay Kit K2065
2026-08-14
The Reactive Oxygen Species Assay Kit K2065 uses the DCFH-DA fluorescent probe for relative ROS measurement in live cells. Its chemistry supports reproducible oxidative stress measurement assay workflows, while appropriate controls and specificity limits remain essential for interpretation.
-
How p38α Conformation Directs Dephosphorylation
2026-08-13
The bioRxiv study reports that selected kinase inhibitors can do more than block p38α catalytic activity: they can also expose the activation-loop phosphothreonine to the WIP1 phosphatase. By combining dephosphorylation assays with X-ray crystallography, the work establishes a structure-guided concept for accelerating kinase deactivation while improving molecular specificity.
-
VE-821 and Viral DNA Replication: ATR-DDR Insights
2026-08-13
Explore how VE-821, a selective ATR kinase inhibitor, can sharpen DNA damage response experiments while offering a hypothesis-driven framework for studying human bocavirus replication. This article connects ATR–Chk1 signaling with the DNMT1-centered findings of a recent PLOS Pathogens study without overstating the antiviral evidence.
-
Hyperthermia Sensitizes BRCA2-Proficient Ovarian Cancer
2026-08-12
Mei et al. show that hyperthermia can reduce BRCA2 protein and make BRCA2-proficient ovarian carcinoma more responsive to the PARP inhibitor niraparib. By combining genomic, molecular, cellular, and mouse-tumor analyses, the study identifies a nonmutational route to homologous-recombination impairment and provides a rationale for hyperthermia–PARP inhibitor combination research.
-
PX-478 in Prenatal Hypoxia–Related ASD Models
2026-08-12
A 2024 rat study tested PX-478 as an intervention in offspring exposed to prenatal hypoxia, linking HIF-1α modulation with improved autism-like behaviors, hippocampal structure, PTEN expression, and VEGF changes. Its staged postnatal design provides a useful framework for studying developmental hypoxia signaling while also highlighting timing-dependent safety considerations.
-
GCG Disrupts SARS-CoV-2 N-Protein Condensates
2026-08-11
The reference study identifies RNA-triggered liquid–liquid phase separation of the SARS-CoV-2 nucleocapsid protein as a mechanistic step in viral biology. It further shows that the green-tea polyphenol (-)-gallocatechin gallate can disrupt N-protein condensation and reduce viral replication, while highlighting how a naturally occurring N-protein variant may alter condensate behavior and interferon antagonism.
-
SMYD2 Inhibition in Cisplatin Renal Fibrosis
2026-08-11
The reference study identifies SMYD2 as a pharmacologically tractable regulator of cisplatin-induced chronic kidney disease, linking its activity to renal fibrosis, epithelial-mesenchymal transition, inflammation, and Smad3/STAT3 signaling. By testing AZ505 and LLY507 in preclinical injury models, the work provides a mechanistic rationale for evaluating SMYD2 inhibition as an antifibrotic strategy while highlighting important limits on translation beyond kidney disease.